New COPD inhaler shows promise in large trial

NCT ID NCT06643078

Completed Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tested a new inhaler called HL231 in 487 Chinese adults with moderate to very severe COPD. Participants used either HL231 or the active comparator Ultibro once daily for 52 weeks. The main goal was to see if HL231 improved lung function (FEV1) after 26 weeks compared to Ultibro. Secondary goals included reducing COPD flare-ups and tracking safety over the full year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HL231 (a combination of indacaterol and glycopyrronium) as an inhaled solution
What this could lead to: If successful, HL231 could offer a new once-daily inhaled treatment option for people with moderate to severe COPD, potentially improving lung function and reducing flare-ups.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The comparison is against an existing drug, so any advantage may be modest. Side effects and long-term safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.